SEARCH

SEARCH BY CITATION

References

  • 1
    Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:16907.
  • 2
    Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:273745.
  • 3
    Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:48194.
  • 4
    Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:13037.
  • 5
    Van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009;68:1395400.
  • 6
    Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005;52:304553.
  • 7
    Holmqvist ME, Wedren S, Jacobsson LT, Klareskog L, Nyberg F, Rantapaa-Dahlqvist S et al. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum 2009;60:28619.
  • 8
    Kremers HM, Crowson CS, Therneau TM, Roger VL, Gabriel SE. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 2008;58:226874.
  • 9
    Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:182939.
  • 10
    Zhang L, Qiao Q, Tuomilehto J, Hammar N, Ruotolo G, Stehouwer CD et al. The impact of dyslipidaemia on cardiovascular mortality in individuals without a prior history of diabetes in the DECODE Study. Atherosclerosis 2009;206:298302.
  • 11
    Nurmohamed MT. Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 2009;8:6637.
  • 12
    Iademarco MF, Barks JL, Dean DC. Regulation of vascular cell adhesion molecule-1 expression by IL-4 and TNF-alpha in cultured endothelial cells. J Clin Invest 1995;95:26471.
  • 13
    Van Zonneveld AJ, De Boer HC, Van Der Veer EP, Rabelink TJ. Inflammation, vascular injury and repair in rheumatoid arthritis. Ann Rheum Dis 2010;69(Suppl 1):i5760.
  • 14
    Turiel M, Atzeni F, Tomasoni L, De Portu S, Delfino L, Bodini BD et al. Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology (Oxford) 2009;48:8349.
  • 15
    Maziere C, Auclair M, Maziere JC. Tumor necrosis factor enhances low density lipoprotein oxidative modification by monocytes and endothelial cells. FEBS Lett 1994;338:436.
  • 16
    Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005;112:66673.
  • 17
    Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005;7:R81724.
  • 18
    Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272:178104.
  • 19
    Carroll L, Hannawi S, Marwick T, Thomas R. Rheumatoid arthritis: links with cardiovascular disease and the receptor for advanced glycation end products. Wien Med Wochenschr 2006;156:4252.
  • 20
    Sitia S, Atzeni F, Sarzi-Puttini P, Di Bello V, Tomasoni L, Delfino L et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev 2009;8:2816.
  • 21
    Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008;121:S2131.
  • 22
    Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how ‘high-grade’ systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:295763.
  • 23
    Foster W, Carruthers D, Lip GY, Blann AD. Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-inflammatory treatment. J Thromb Thrombolysis 2010;29:43742.
  • 24
    Pemberton PW, Ahmad Y, Bodill H, Lokko D, Hider SL, Yates AP et al. Biomarkers of oxidant stress, insulin sensitivity and endothelial activation in rheumatoid arthritis: a cross-sectional study of their association with accelerated atherosclerosis. BMC Res Notes 2009;2:83.
  • 25
    Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002;39:105.
  • 26
    Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:123641.
  • 27
    Laurent S, Katsahian S, Fassot C, Tropeano AI, Gautier I, Laloux B et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003;34:12036.
  • 28
    Wong M, Toh L, Wilson A, Rowley K, Karschimkus C, Prior D et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003;48:819.
  • 29
    Hannawi S, Marwick TH, Thomas R. Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 2009;11:R51.
  • 30
    Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005;46:1949.
  • 31
    Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:14327.
  • 32
    Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000;151:47887.
  • 33
    Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay MA. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 2009;38:36671.
  • 34
    Georgiadis AN, Voulgari PV, Argyropoulou MI, Alamanos Y, Elisaf M, Tselepis AD et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 2008;38:1319.
  • 35
    Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:132430.
  • 36
    Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008;93:114352.
  • 37
    Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ et al. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008;31:51721.
  • 38
    Chiang KH, Huang PH, Huang SS, Wu TC, Chen JW, Lin SJ. Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients. Coron Artery Dis 2009;20:26773.
  • 39
    Kageyama Y, Takahashi M, Ichikawa T, Torikai E, Nagano A. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008;26:7380.
  • 40
    De Leeuw LK, Graaff R, De VR, Dullaart RP, Smit AJ, Kallenberg CG et al. Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2007;46:15516.
  • 41
    Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:32531.
  • 42
    Dessein PH, Joffe BI. Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis. Clin Exp Rheumatol 2006;24:1617.
  • 43
    Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:11737.
  • 44
    Wong M, Oakley SP, Young L, Jiang BY, Wierzbicki A, Panayi G et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68:127784.
  • 45
    Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:21847.
  • 46
    Kerekes G, Soltesz P, Der H, Veres K, Szabo Z, Vegvari A et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009;28:70510.
  • 47
    Hafstrom I, Rohani M, Deneberg S, Wornert M, Jogestrand T, Frostegard J. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study. J Rheumatol 2007;34:18106.
  • 48
    Kageyama Y, Takahashi M, Nagafusa T, Torikai E, Nagano A. Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatol Int 2008;28:24551.